Stock listing
A426UV Stock Price, News, Filings & Events — Fibrobiologics, Inc.
Selected listing: A426UV · LSX · EUR · DE
This page tracks Fibrobiologics, Inc.'s A426UV:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A426UV:LSX. A426UV:LSX is the stock-level entry point for investors researching Fibrobiologics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fibrobiologics, Inc. (ticker: FBLG) is a public company operating in the American market, with a market capitalization of approximately $4.33 million. The company focuses on developing innovative solutions in the field of biotechnology. As a publicly traded entity, Fibrobiologics is committed to advancing its research and development efforts.

- Ticker
- A426UV:LSX
- Asset type
- Stock
- Market cap
- $9.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LSX
- Currency
- EUR
Fibrobiologics, Inc. A426UV:LSX stock context
This page tracks Fibrobiologics, Inc.'s A426UV:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A426UV:LSX. A426UV:LSX is the stock-level entry point for investors researching Fibrobiologics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fibrobiologics, Inc. (ticker: FBLG) is a public company operating in the American market, with a market capitalization of approximately $4.33 million. The company focuses on developing innovative solutions in the field of biotechnology. As a publicly traded entity, Fibrobiologics is committed to advancing its research and development efforts.
Latest news from Fibrobiologics, Inc.
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
September 1, 2026
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
August 27, 2026
FibroBiologics Regains Compliance with Nasdaq Trading Rules
August 26, 2026
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
Research Fibrobiologics, Inc.
Fibrobiologics, Inc. investor report
Review AI stock analysis and investor report context for A426UV:LSX.
Fibrobiologics, Inc. company profile
View the public company page for Fibrobiologics, Inc. on 6ix.
Fibrobiologics, Inc. news
Read company news and market updates connected to Fibrobiologics, Inc..
Fibrobiologics, Inc. investor events
Find investor webinars, events, and replay context for Fibrobiologics, Inc..
Alternate listings
FBLG:NASDAQ
US · USD
Alternate listing for Fibrobiologics, Inc.; the primary context on this page is A426UV:LSX.
FBLG:BOATS
US · USD
Alternate listing for Fibrobiologics, Inc.; the primary context on this page is A426UV:LSX.
SG00:FWB
DE · EUR
Alternate listing for Fibrobiologics, Inc.; the primary context on this page is A426UV:LSX.
A426UV:LS
DE · EUR
Alternate listing for Fibrobiologics, Inc.; the primary context on this page is A426UV:LSX.